Parkinson's disease and working capacity

Movement Disorders

Volumn 21, Issue 12, 2006, Pages 2187-2191

  Martikainen, Kirsti K ^a   Luukkaala, Tiina H ^b   Marttila, Reijo J ^c  

^a The Finnish Parkinson Association and Foundation   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Employment; Parkinson's disease; Rehabilitation; Retirement

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FINLAND; HUMAN; JOB ADAPTATION; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; RETIREMENT; SELF CONCEPT; SYMPTOMATOLOGY; WORK CAPACITY; WORK SCHEDULE;

ADULT; AGED; DISABILITY EVALUATION; EMPLOYMENT; FEMALE; FINLAND; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; QUESTIONNAIRES; RETIREMENT; WORK;

EID: 33846455413     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21171     Document Type: Article

References (21)

1. Kuopio AM, Marttila RJ, Helenius H, et al. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 1999;52:302-308.
2. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999;16:59-69.
3. Rubenstein LM, DeLeo A, Chrischilles EA. Economic and health-related quality of life considerations of new therapies in Parkinson's disease. Pharmacoeconomics 2001;19:729-752.
4. Chrischilles EA, Rubenstein LM, Voelker MD, et al. The health burdens of Parkinson's disease. Mov Disord 1998;13:406-413.
5. Clarke CE, Zobkiw RM, Gullaksen E. Quality of life and care in Parkinson's disease. Br J Clin Pract 1995;49:288-293.
6. Barth F, Baum B, Bremen D, Meuser T, Jost WH. Die indirekten Kosten des idiopathischen Parkinson-Syndroms. Fortschr Neurol Psychiatry 2005;73:187-191.
7. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord 2005;20:1449-1454.
8. Banks P, Lawrence M. The Disability Discrimination Act, a necessary, but not sufficient safeguard for people with progressive conditions in the workplace? The experiences of younger people with Parkinson's disease. Disabil Rehabil 2006;28:13-24.
9. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
10. Schrag A, Hovris A, Morley D, et al. Young- versus old-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord 2003;18:1250-1256.
11. Kuopio A-M. Parkinson's disease: occurrence, risk factors, and quality of life. Thesis. Turku: University of Turku; 2000. p 82.
12. Statistical Yearbook of Finland 2003. Gummerus kirjapaino Oy, Jyväskylä 2003. p 363-364.
13. Späte HF, Gemende G, Gemende I. Psychosoziale Aspecte der langzeitbetreuung von Parkinsonkranken. Psychiatr Neurol Med Psychol (Leipz) 1988;40:385-394.
14. Spliethoff-Kamminga NGA, Zwinderman AH, Springer MP, Roos RAC. Difference in quality of life and psychosocial well-being between Parkinson disease patient members and non-members of the Dutch Parkinson Disease Association. In: Noelle GA, Spliethoff-Kamminga NGA, editors. Psychosocial Problems in Parkinson's Disease. Leiden: Grafische Producties, Universitair Facilitair Bedrijf, 2004. p 79-89.
15. Dodel RC, Singer M, Köhne-Volland R, et al. Costs of illness in Parkinson disease. A retrospective 3-month analysis of direct costs. Nervenarzt 1997;68:978-984.
16. Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005;23:817-836.
17. Singer E. Social costs of Parkinson's disease. J Chron Dis 1973; 26:243-254.
18. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997;45:844-849.
19. Keränen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003;9:163-168.
20. Dodel RC, Singer M, Köhne-Volland R, et al. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998;14:299-312.
21. Bryson HM, Milne RJ, Chrisp P. Selegiline: an appraisal of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease. Pharmacoeconomics 1992;2:118-136.